A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors

Solid Tumor Clinical Trial

Official title:

An Open-label, Multi-Centered, Dose Escalation Phase Ib Study (Expansion Stage) of Epitinib (HMPL-813) in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02590952
• Other study ID #: 2010-813-00CH1
• Status: Completed
• Phase: Phase 1
• Start date: October 31, 2011
• Est. completion date: April 30, 2019

Study information

• Verified date: February 2019
• Source: Hutchison Medipharma Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor. Epitinib has demonstrated strong inhibitory effects on multiple tumors with overexpressed EGFR or sensitive EGFR mutations in pre-clinical setting. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of Epitinib.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 108
• Est. completion date: April 30, 2019
• Est. primary completion date: April 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Histopathology confirmed solid tumors

• Failed to standard treatment or no standard treatments for uncontrolled, recurrent and/or metastatic advance tumor (whatever previous surgery conditions)

• Age 18-70

• ECOG 0-2, and no worse within 7days

• Life expected > 12 weeks

• written informed consent form voluntarily

• For dose expansion cohort, subjects must be eligible for the following inclusion criteria:

• EGFR sensitizing mutation in exon 19 deletion or exon 21(L858R).

• Histologically or cytologically confirmed advanced NSCLC with brain metastasis. No prior brain radiotherapy or brain metastasis progressed after brain radiotherapy delivered assessed by RECIST 1.1.

• No prior EGFR-TKI treatment. Or subjects who treated with EGFR-TKI developed brain lesions during EGFR-TKI therapy or the existing brain lesions progressed but with stable extra-cranial lesions.

• Treatment failure of prior systemic chemotherapy for locally advanced or metastasized NSCLC or intolerance to chemotherapy. Or subjects with disease relapse after treated with adjuvant or neo-adjuvant chemotherapy.

• With at least one measurable disease ( RECIST 1.1).

Exclusion Criteria:

• Lab testing within 2 weeks before enrolled, AND ANC<1.5×10 9/L, platelet<75×10 9/L, or Hb<9g/dL,

• Serum Total Bilirubins > ULN, ALT/AST=ULN without liver metastasis, or ALT/AST=2.5ULN with liver metastasis

• Serum creatinine >1.5ULN or creatinine clearance <40ml/min

• Diastolic systolic pressure=140mmHg or systolic diastolic pressure=90mmHg whatever anti-hypertension drug used,

• Serum potassium <4.0mmol/L(whenever potassium implemented), serum calcium(ionic or albumin-type calcium) or serum magnesium outside normal ranges(whenever implemented)

• Within previous 4 weeks treated by systemic anti-tumor therapy, or radiotherapy, immune therapy, biological or hormonal therapy, and clinical trials.

• Unrecovered from any previous therapy related toxicity to CTCAE 0 or 1or unrecovered from any previous surgery

• Known dysphagia or drug malabsorption

• Active infections such as acute pneumonia, hepatitis B immune-active periodphase

• ocular surface diseases or dry eye syndrome

• skin disease with obvious symptoms and signs

• significant cardiovascular disease, including II-IV atrioventricular block, and acute myocardial infarction within 6 months, significant angina or Coronary artery bypass graft within 6 months

• Female patients who are pregnant or feeding, or childbearing potential patient with pregnant testing positive

• Any abnormal of clinical and laboratory so that patients unsuitable to attend the trial sine in the opinion of the investigator

• Patients unable to comply with the protocol since significant psychological or psychogenic abnormal

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• Epitinib
The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.

Locations

Country	Name	City	State
China	Guangdong General Hospital	Guangzhou

Sponsors (1)

Lead Sponsor	Collaborator
Hutchison Medipharma Limited

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	incidence of all types/grades of adverse events	for each patient, adverse events are collected from the date of consent until 30 days after trial discontinuation	from first patient in till 30 days after the last patient last visit. It is estimated that last patient last visit happens in Oct 2016.
Secondary	Objective Response Rate		An average of one year
Secondary	Area under the plasma concentration versus time curve (AUC)	Based on single-dose PK result, multi-dose stage subjects take epitinib either once a day or twice a day. For twice a day epitinib uptake, on day 1/14/28, PK samples are collected predose, 1, 4, 8, 12 hours post-dose in the morning and 4 hours post-dose in the evening. On day 2/3/7, PK samples are collected predose, 4, 12 hours post-dose in the morning and 4 hours post-dose in the evening. On day 15/29/56, PK samples are collected predose in the morning.; For once a day epitinib uptake, on day 1/14/28 PK samples are collected predose, 0.5, 1, 2, 4, 6, 8, 12 hours post-dose. On day 7, PK samples are collected predose and 4 hours post-dose. On day 2/15/29/56, PK samples are collected predose in the morning.	At single-dose stage (day 1-day 7): predose, 0.5,1, 2, 3, 4, 5, 6, 8,12,24, 36, 48, 72, 144 hours post-dose.
Secondary	Peak Plasma Concentration (Cmax)	Based on single-dose PK result, multi-dose stage subjects take epitinib either once a day or twice a day. For twice a day epitinib uptake, on day 1/14/28, PK samples are collected predose, 1, 4, 8, 12 hours post-dose in the morning and 4 hours post-dose in the evening. On day 2/3/7, PK samples are collected predose, 4, 12 hours post-dose in the morning and 4 hours post-dose in the evening. On day 15/29/56, PK samples are collected predose in the morning.; For once a day epitinib uptake, on day 1/14/28 PK samples are collected predose, 0.5, 1, 2, 4, 6, 8, 12 hours post-dose. On day 7, PK samples are collected predose and 4 hours post-dose. On day 2/15/29/56, PK samples are collected predose in the morning.	At single-dose stage (day 1-day 7): predose, 0.5,1, 2, 3, 4, 5, 6, 8,12,24, 36, 48, 72, 144 hours post-dose.